Why Adaptive Biotechnologies Is Drawing Attention Now
Adaptive Biotechnologies (ADPT) is back on investor radars after recent share price weakness. The stock has shown negative returns over the past week, month, and past 3 months, while still delivering a strongly positive 1 year total return.
See our latest analysis for Adaptive Biotechnologies.
The recent 1 day share price decline of 11.1% to US$12.41 adds to weak short term momentum, with 30 day and 90 day share price returns both firmly negative. However, the 1 year total shareholder return of 61.8% still reflects earlier strength.
If you are looking beyond a single healthcare name, this could be a useful moment to scan for other opportunities in the sector and see what stands out in 34 healthcare AI stocks
So with Adaptive Biotechnologies delivering a 62% 1 year total return yet trading around a 68% discount to the average analyst price target, is this a fresh opportunity or a market that has already priced in future growth?
Most Popular Narrative: 40.5% Undervalued
Adaptive Biotechnologies' most widely followed narrative points to a fair value of US$20.86 per share versus the last close of US$12.41, framing a sizeable valuation gap built on detailed growth and margin assumptions.
Ongoing development of AI-driven TCR-antigen prediction models and a robust immune medicine pipeline creates future optionality for high-margin pharma partnerships and new diagnostic indications, leveraging secular trends in data-driven healthcare and personalized therapeutics, supporting sustained long-term earnings growth.
Want to see what kind of revenue ramp, margin lift and future earnings multiple are baked into that fair value estimate? The narrative spells out a specific growth runway, an assumed path to healthier profitability and a premium P/E that together underpin the US$20.86 figure.
Result: Fair Value of $20.86 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if prolonged company wide losses or pressure on clonoSEQ reimbursement and pricing begin to weigh more heavily on the MRD growth case.
Find out about the key risks to this Adaptive Biotechnologies narrative.
Another Way to Look at Value
The first narrative leans on long term growth and margins to argue Adaptive Biotechnologies is 40.5% undervalued at a fair value of US$20.86 per share. However, Simply Wall St's own work using a P/S based fair ratio of 5.7x versus the current 6.9x suggests the shares look expensive. Which view feels closer to your own assumptions?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals across price moves and valuation views, this is a moment to look at the full picture promptly and decide where you stand, starting with 3 key rewards and 2 important warning signs
Ready to uncover more opportunities?
If you stop with just one stock, you risk missing ideas that could fit your goals better, so use curated lists to widen your options quickly.
- Target potential value with a focus on quality by scanning 61 high quality undervalued stocks that balance fundamentals with pricing.
- Prioritise resilience and sleep-at-night holdings by reviewing 67 resilient stocks with low risk scores that score well on risk metrics.
- Spot earlier stage opportunities with solid underpinnings by checking the screener containing 26 high quality undiscovered gems that many investors may be ignoring.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com